Back

‘Highest risk–highest benefit’ strategy: a pragmatic, cost-effective approach to targeting use of PCSK9 inhibitor therapies

European Heart Journal

11 December 2017
Organised by: Logo
Read full article
ESC Journals PREVENTIVE CARDIOLOGY Risk Factors and Prevention

Contributors

Lieven Annemans
Lieven Annemans

Author

Ghent University Ghent , Belgium

Chris J Packard
Chris J Packard

Author

Andrew Briggs
Andrew Briggs

Author

Kausik K Ray
Kausik K Ray

Author

You may be interested in
thumbnail
Congress Presentation
Evaluating risk-based allocation strategies for PCSK9 inhibitors: results from a simulation study in a contemporary ASCVD cohort
26 August 2023
thumbnail
Congress Presentation
Cost-effectiveness of statin therapy in categories of patients in the UK
27 August 2022
thumbnail
Webinar
Post-ACS management of dyslipidaemia: tips and tricks from real world experiences
16 December 2020
thumbnail
Congress Presentation
Effectiveness of PCSK9 inhibitors in homozygous familial hypercholesterolemia: insights from a Saudi Arabia genetic population
3 April 2025

ESC 365 is supported by

novartis Explore sponsored resources
novo-nordisk Explore sponsored resources